ATOS - Atossa Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Seattle,
United States
Type: Equity
ATOS price evolution
ATOS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.57 | $94.14 | $99.5 | $103.98 |
| Short term investments | ||||
| Net receivables | $0.74 | $0.74 | ||
| Inventory | ||||
| Total current assets | $92.22 | $97.65 | $106 | $110.87 |
| Long term investments | $1.71 | $1.71 | $1.71 | $4.7 |
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4.03 | $4.05 | $2.35 | $5.33 |
| Total investments | $1.71 | $1.71 | $1.71 | $4.7 |
| Total assets | $96.25 | $101.69 | $108.36 | $116.2 |
| Current liabilities | ||||
| Accounts payable | $0.81 | $0.72 | $1.17 | $1.44 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.24 | $3.44 | $3.48 | $2.94 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.24 | $3.44 | $3.48 | $2.94 |
| Shareholders' equity | ||||
| Retained earnings | -$186.29 | -$178.53 | -$172.31 | -$162.47 |
| Other shareholder equity | ||||
| Total shareholder equity | $91.02 | $98.25 | $104.88 | $113.26 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $88.57 | $111 | $136.49 | $39.66 |
| Short term investments | ||||
| Net receivables | $0.74 | $1.07 | $0.63 | |
| Inventory | ||||
| Total current assets | $92.22 | $118.2 | $141.24 | $42.77 |
| Long term investments | $1.71 | $4.7 | ||
| Property, plant & equipment | $0.02 | $0.04 | ||
| Goodwill & intangible assets | $0.01 | |||
| Total noncurrent assets | $4.03 | $5.33 | $0.02 | $0.07 |
| Total investments | $1.71 | $4.7 | ||
| Total assets | $96.25 | $123.53 | $141.26 | $42.84 |
| Current liabilities | ||||
| Accounts payable | $0.81 | $2.96 | $1.72 | $1.59 |
| Deferred revenue | ||||
| Short long term debt | $0.02 | |||
| Total current liabilities | $5.24 | $5.57 | $3.13 | $15.67 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.02 | |||
| Total liabilities | $5.24 | $5.57 | $3.13 | $15.67 |
| Shareholders' equity | ||||
| Retained earnings | -$186.29 | -$156.19 | -$129.23 | -$111.9 |
| Other shareholder equity | $0.62 | |||
| Total shareholder equity | $91.02 | $117.96 | $138.14 | $27.17 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $5.65 | $4.47 | $3.71 | $3.51 |
| Selling, general & administrative | $3.37 | $3 | $4.09 | $3.59 |
| Total operating expenses | $9.02 | $7.47 | $7.79 | $7.1 |
| Operating income | -$9.02 | -$7.47 | -$7.79 | -$7.1 |
| Income from continuing operations | ||||
| EBIT | -$7.75 | -$6.23 | -$9.83 | -$6.28 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$7.75 | -$6.23 | -$9.83 | -$6.28 |
| Income (for common shares) | -$7.75 | -$6.23 | -$9.83 | -$6.28 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $17.33 | $15.08 | $9.21 | $6.61 |
| Selling, general & administrative | $14.04 | $12.61 | $11.31 | $8 |
| Total operating expenses | $31.38 | $27.69 | $20.52 | $14.61 |
| Operating income | -$31.38 | -$27.69 | -$20.52 | -$14.61 |
| Income from continuing operations | ||||
| EBIT | -$30.09 | -$26.96 | -$20.61 | -$17.83 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$30.09 | -$26.96 | -$20.61 | -$17.83 |
| Income (for common shares) | -$30.09 | -$26.96 | -$20.61 | -$22.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$7.75 | -$6.23 | -$9.83 | -$6.28 |
| Operating activities | ||||
| Depreciation | $0.01 | $0 | $0 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.52 | $0.93 | $1.6 | $1.57 |
| Total cash flows from operations | -$5.57 | -$3.88 | -$4.46 | -$7.02 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.01 | ||
| Investments | ||||
| Total cash flows from investing | -$0 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1.48 | |||
| Net borrowings | ||||
| Total cash flows from financing | -$1.48 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.57 | -$5.36 | -$4.48 | -$7.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$30.09 | -$26.96 | -$20.61 | -$17.83 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.01 | $0.02 | $0.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.62 | $6.79 | $5.27 | $3.02 |
| Total cash flows from operations | -$20.94 | -$20.76 | -$16.47 | -$11.57 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.03 | -$0.01 | -$0.01 |
| Investments | -$4.7 | |||
| Total cash flows from investing | -$0.01 | -$4.73 | -$0.01 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1.48 | $113.88 | $33.62 | |
| Net borrowings | ||||
| Total cash flows from financing | -$1.48 | $113.3 | $38.55 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.43 | -$25.49 | $96.82 | $26.97 |
News
Fundamentals
| Market cap | $187.96M |
|---|---|
| Enterprise value | $99.39M |
| Shares outstanding | 125.30M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$30.07M |
| EBIT | -$30.09M |
| Net Income | -$30.09M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -6.25 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -3.31 |
| EV/EBIT | -3.30 |
| P/S ratio | N/A |
| P/B ratio | 2.07 |
| Book/Share | 0.73 |
| Cash/Share | 0.71 |
| EPS | -$0.24 |
|---|---|
| ROA | -28.49% |
| ROE | -29.55% |
| Debt/Equity | 0.06 |
|---|---|
| Net debt/EBITDA | 2.77 |
| Current ratio | 17.61 |
| Quick ratio | 17.61 |